Skip to main content
. 2020 Oct 2;18:374. doi: 10.1186/s12967-020-02518-2

Table 1.

Epidemiological studies of whole cannabis for anxiety (part 1)

Study Data source Number of participants Route of administration Dosage Percent of respondents using for anxiety
Sexton et al. 2016 [50] Recruited via social media and Cannabis dispensaries in Washington State 1429 Inhalation (84.1%), Concentrates also typically inhaled (6.4%), Oral (8%), Topical: (0.6%), Fresh juice (0.5%), Other (0.4%) 47.6% reported using 1–4 times per day 14.9% reported using 5–10 times per day 12.2% reported using all day, every day. 25.3% reported using less than once a day Dose is N/A 58.1%
Lintzeris et al. 2018 [51] Recruited via online media and at professional and consumer forums 1748

Most frequent route was inhalation (83.4%)

Oral Topical, suppository, and vaporiser routes used by only 29.4% of respondents

N/A 51%
Turna et al. 2019 [56] An online survey was disseminated to all authorized CMP users registered with Canadian medicinal cannabis supplier Tilray 2032 47.6% reported vaporising as the preferred mode of delivery, 21.4% preferred oral ingestion (edibles, oils, etc.) 18.5% preferred joints 35% used < 1 g/day 42% used 1–2 g/day 23% used ≥ 3 g/day. 43.7%
Kosiba et al. 2019 [52] Data were extracted from 13 studies that included participants from over 30 countries 6665 N/A N/A 52%